A Phase 1, Open-Label, Randomized, Single-Dose, 2-Way Crossover Study To Determine Bioequivalence Of 4 Mg Fesoterodine SR Tablet Between Formulation D And Formulation E(1) In Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 08 Sep 2010
At a glance
- Drugs Fesoterodine (Primary)
- Indications Overactive bladder
- Focus Pharmacokinetics
- Sponsors Pfizer
- 19 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Apr 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 22 Nov 2008 New trial record.